Business Context and Reporting Period
This Form 8-K, dated August 23, 2022, is filed by LMF Acquisition Opportunities, Inc. (the "Company"), a special purpose acquisition company (SPAC). The filing details material definitive agreements entered into on August 23, 2022, in connection with a proposed business combination with SeaStar Medical, Inc. ("SeaStar"). The Company is an emerging growth company.
Key Financial Metrics and Agreements
The filing outlines two primary capital-raising mechanisms rather than historical operating financials:
- Equity Line of Credit: The Company entered into a Common Stock Purchase Agreement with Tumim Stone Capital LLC ("Tumim") for a total commitment of up to $100 million. Tumim is obligated to purchase shares at the Company's discretion over a 24-month period following the business combination closing.
- PIPE Investment: The Company secured a private investment in public equity (PIPE) of $7 million from third-party investors. This includes 700,000 shares of Class A common stock at $10.00 per share and warrants to purchase 700,000 shares at an exercise price of $11.50 per share.
- Commitment Fee: The Company agreed to pay Tumim a commitment fee of $2.5 million, to be paid in shares of common stock (Commitment Shares) prior to the filing of the initial registration statement, or in cash if the agreement is terminated early.
Material Changes and Conditions
The obligations under the Purchase Agreement with Tumim are contingent upon the closing of the Business Combination with SeaStar and the effectiveness of a registration statement filed with the SEC. The agreement will not become effective until these conditions are met. The PIPE Investment is scheduled to close immediately prior to the Closing Date of the Business Combination. The filing notes that the Company has covenanted not to enter into other equity lines of credit or variable rate transactions during the term of the Tumim agreement.
Outlook, Risks, and Contingencies
Outlook and Use of Proceeds: Proceeds from the Tumim agreement are expected to be used for working capital and general corporate purposes. The PIPE Investment provides immediate capital upon the closing of the merger.
Risks and Termination: The Purchase Agreement may be terminated by Tumim if the Closing Date does not occur before December 1, 2022, or in the event of a material adverse effect, change of control, or failure to file the initial registration statement. If the Company terminates the agreement but the Business Combination is consummated, the $2.5 million commitment fee remains payable.
Unregistered Sales: Securities issued under these agreements are being sold in reliance on exemptions from registration requirements under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Investor Verification Checklist
- Verify the status of the Business Combination closing with SeaStar Medical, Inc., as the Tumim agreement is contingent upon this event.
- Confirm the filing and effectiveness of the Initial Registration Statement required to activate the Tumim Purchase Agreement.
- Monitor the December 1, 2022 deadline for the Closing Date to avoid automatic termination rights for Tumim.
- Review the calculation of the $2.5 million Commitment Fee, specifically the weighted average trading price used to determine the number of Commitment Shares to be issued.
- Check for any subsequent filings regarding the actual issuance of shares under the $100 million Tumim commitment or the $7 million PIPE investment.